Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups Meeting Abstract
| Authors: | Chari, A.; Kaufman, J. L.; Laubach, J. P.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; Shah, N.; Bumma, N.; Holstein, S. A.; Costello, C.; Jakubowiak, A.; Wildes, T. M.; Orlowski, R. Z.; Shain, K. H.; Cowan, A. J.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T. S.; Richardson, P. G.; Usmani, S.; Voorhees, P. M. |
| Abstract Title: | Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 7278 |
| End Page: | 7281 |
| Language: | English |
| ACCESSION: | WOS:000893230300128 |
| DOI: | 10.1182/blood-2022-162339 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
